Genelux (GNLX) vs Minerva Neurosciences (NERV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed Genelux (GNLX) over the past year, losing 5.6% versus a loss of 57.7%. Minerva Neurosciences is the larger company by market cap ($112.2 million vs $109.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | NERV |
|---|---|---|
| Share price | $2.42 | $2.35 |
| Market cap | $109.49M | $112.21M |
| 1-day change | -2.42% | -2.89% |
| YTD return | -44.50% | -41.54% |
| 1-year return | -57.69% | -5.62% |
| 5-year return | — | -76.87% |
| EPS (TTM) | $-0.86 | $-36.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.00K | — |
| Revenue growth (YoY) | 0.00% | — |
| Net income (latest FY) | $-32.15M | $-293.42M |
| Operating margin | -415175.00% | — |
| Net margin | -401812.50% | — |
| 52-week high | $8.54 | $12.46 |
| 52-week low | $2.29 | $2.28 |
| Distance from 52-week high | -71.65% | -81.14% |
| Analyst consensus | none | none |
| Avg. price target upside | +678.10% | +339.57% |
| Average volume | 288.93K | 181.64K |
| Shares outstanding | 45.25M | 47.75M |
| Employees | 25 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed GNLX by 52.1 percentage points over the past year.
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
GNLX vs NERV FAQ
Which is bigger, Genelux or Minerva Neurosciences?
Minerva Neurosciences (NERV) is larger, with a market capitalization of $112.21M compared with $109.49M for Genelux (GNLX).
Which stock has performed better over the past year, GNLX or NERV?
NERV returned -5.62% over the past 12 months, compared with -57.69% for GNLX (price return, excluding dividends). Past performance does not predict future results.
Are Genelux and Minerva Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.